
Denosumab noninferior to zoledronic acid in the treatment of bone metastasis
How to Cite
OrthoEvidence. Denosumab noninferior to zoledronic acid in the treatment of bone metastasis. ACE Report. 2014;3(2):15. Available from: https://myorthoevidene.com/AceReport/Report/5244
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
1,779 patients with solid tumours (except breast and prostate) or myeloma, as well as at least 1 bone metastasis or osteolytic lesion as confirmed by radiographic imaging were randomized to receive either monthly subcutaneous injections of denosumab or intravenous administration of zoledronic acid to compare the efficacy and safety of these two treatments. Results at 34 months indicated that denos...
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!

Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.